Combo Products Meeting Will Address Cross-Labeling, Dual Applications
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic ultrasound, magnetic resonance imaging and contrast agent companies will hold a series of meetings with FDA to address issues related to their respective device and drug premarket approvals